Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma

Maria Bach Laursen(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Julie Støve Bødker(Chr. Hansen (Denmark)), Steffen Falgreen(Chr. Hansen (Denmark)), Suzette Sørensen(North Denmark Region), Martin Bøgsted(Chr. Hansen (Denmark)), Jakob Madsen(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Malene Krag Kjeldsen(Chr. Hansen (Denmark)), Tarec Christoffer El‐Galaly(Aalborg University Hospital)

Experimental Hematology

July 27, 2014

10.1016/j.exphem.2014.07.263

Cited by 18

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

|Leukemia|2015|256